Cellectis to Report Third Quarter 2022 Financial Results
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30th, 2022, on Thursday, November 3rd, 2022, after the close of the US market.
Related news for (CLLS)
- MoBot alert highlights: NASDAQ: RCAT, NASDAQ: LOBO, NASDAQ: IPA, NASDAQ: YHC, NASDAQ: CLLS (07/14/25 03:00 PM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 03/14/25 08:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 03/14/25 07:00 AM
- Breaking News: MoBot’s Latest Update as of 03/14/25 06:00 AM
- MoBot alert highlights: NASDAQ: CLLS, NASDAQ: MRM, NASDAQ: BTOG (03/14/25 05:00 AM)